10.Neelapu SS, Chavez J, Sehgal AR, et al. 3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymph...
CAR-T细胞治疗组、基于维泊妥珠单抗治疗组和基于tafasitamab治疗组的中位随访时间分别为10.0、6.6和4.3个月。 Epcoritamab组CR率与CAR-T细胞治疗组基本相当(41.7% vs. 36.5%),OR为1.1(95% CI: 0.8, 1.6;P= 0.472);Epcoritama...
弥漫大B细胞淋巴瘤（diffusedlarge B cell lymphoma，DLBCL）是最常见的非霍奇金淋巴瘤亚型，其治疗主要...
9. Dull J, et al. Long-term analyses from L-MIND, a phase II study of Tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). 2021 ASCO Abstract 7513. 10. Caimi P, etal. Duration of response to Lonca...
作者随后构建骨髓嵌合小鼠确认BclxLtgA20-/- B细胞诱导自限免疫反应有效抑制BclxLtgA20wt/-引起的自身免疫,表明T细胞依赖B细胞内源高反应环境发挥相反的作用,并揭示强高反应性B细胞诱导自限T细胞反应。之后,作者分离CD3ε-/-Niktg、CD3ε-/-NiktgA20wt/-和CD3ε-/-Niktg A20-/-小鼠的B细胞行RNA-seq,GSEA...
英文名称Mouse Bcl-2 (B-Cell Leukemia/Lymphoma 2) ELISA Kit中文名称小鼠B细胞淋巴瘤因子2(Bcl-2)酶联免疫吸附测定试剂盒货号kL-M0175c种属Mouse/小鼠规格96T/Kit (8*12 strips) 48T/Kit (8*6 strips)检测方法双抗体夹心法检测范围15.625~1000pg/mL灵敏度9.375pg/mL ...
造血干细胞移植(hematopoietic cell transplantation,HCT)是很多恶性和非恶性疾病的重要治疗选择。移植所需多能造血 干细胞通常来自于亲缘或非亲缘供者的、骨髓或外周血。脐带血是婴儿出生后留在脐带和胎盘中的血液,已成为同种异体造血干细胞的备选来源。供者和受者的I类和II类HLA单倍型匹配是异基因造血干细胞移植成功...
NeoBiotechnologies Anti-Granzyme B (NK/T-Cell Lymphoma Marker) Recombinant Monoclonal (rGZMB/4538), Catalog # 3002-MSM8-P1. Tested in Western Blot (WB), Immunohistochemistry (Paraffin) (IHC (P)) and Immunoelectrophoresis (IE) applications. This antibody
根据细胞起源(Cell-of-origin, COO)的不同将DLBCL分为3类,即生发中心B细胞样(Germinal center B-cell like, GCB)亚型、活化B细胞样(Activated B cell-like,ABC)亚型和其它第3亚型[1]。基于利妥昔单抗(Rituximab)的免疫化疗R-CHOP为DLBCL的标准一线治疗方案,约60%的患者可获得长期生存,GCB亚型预后优于ABC亚型...
Muscle-invasive bladder cancer (MIBC) is a highly aggressive disease with a poor prognosis. B cells are crucial factors in tumor suppression, and tertiary lymphoid structures (TLSs) facilitate immune cell recruitment to the tumor microenvironment (TME).